



an Open Access Journal by MDPI

## Regulatory T Cells in Neuroimmunological Disease Therapeutics

Guest Editor:

### Dr. Michel Edwar Mickael

Department of Experimental  
Genomics, Institute of Genetics  
and Animal Biotechnology,  
Polish Academy of Sciences,  
Postępu 36A, 05-552 Garbatka,  
Poland

Deadline for manuscript  
submissions:  
**closed (31 July 2024)**

### Message from the Guest Editor

#### Topics of Interest:

- **Autoimmune Diseases:** Explore the involvement of Tregs in autoimmune neuroimmunological diseases. Investigate Treg-based therapies aimed at modulating autoimmunity.
- **Immunomodulation:** Examine how Tregs can be harnessed to modulate the immune responses contributing to neuroinflammation. Discuss the impact of existing immunomodulatory therapies on Treg function.
- **Neuroprotection:** Investigate the neuroprotective effects of Tregs in various neuroimmunological diseases. Explore how Tregs can limit immune-mediated neuronal damage, reduce inflammation, and support tissue repair.
- **Immune–Brain Crosstalk:** Delve into the role of Tregs in influencing the communication between the immune system and the central nervous system. Explore Treg-based approaches for conditions associated with gut dysbiosis, such as autism spectrum disorders and mood disorders.
- **Treg-Based Therapies:** Present research on Treg-based therapies tailored to specific neuroimmunological diseases. Discuss strategies for Treg isolation, expansion, and administration, as well as the potential of genetically modified Tregs.



[mdpi.com/si/184394](https://mdpi.com/si/184394)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)